Montega Reiterates Buy on AlzChem With EUR 220 Price Target

Bitget2026/10/30 08:54

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Montega reiterated its Buy rating on AlzChem on Oct. 30, 2026, maintaining a 12-month price target of EUR 220.
The research firm flagged uncertainty over the US nitroguanidine project, which is undergoing cost and planning optimization.
Montega viewed the roughly EUR 600 million annual revenue target as ambitious, requiring nearly 14% fourth-quarter growth.
Third-quarter EBITDA fell 3.5% to EUR 28.7 million amid higher energy and raw material costs alongside capacity startup expenses.
The analysts considered the growth case intact, citing progress on German nitroguanidine and creatine capacity expansions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27244) on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Montega Reiterates Buy on AlzChem With EUR 220 Price Target

You may also like

Crypto prices